Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial

Official title:
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Clinical Trial Summary

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: - What are the demographic and clinical characteristics of metastatic prostate cancer patients? - How are metastatic prostate cancer patients currently treated and how effective are these treatments? - How does the development of castration-resistance affect patient outcomes? - What is the economic burden of metastatic prostate cancer?

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05701007
Study type Observational
Source Pfizer
Contact
Status Completed
Phase
Start date February 13, 2023
Completion date April 10, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05208229 - The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
Suspended NCT05425862 - Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Active, not recruiting NCT03480646 - ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT03874884 - 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Terminated NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Phase 1
Terminated NCT04052204 - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03724747 - Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Completed NCT04516161 - EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Withdrawn NCT02130947 - Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide N/A